CG reports its Q1 2026 results on April 30 carrying the weight of a gold-sector-wide selloff — and the question is whether its own fundamentals can hold up against the macro-driven pressure.
The price action tells the most immediate story. The stock closed Wednesday at CAD 23.90, down 3% on the day and off 7.6% for the week. That drawdown is in line with a broad pullback across gold peers: AEM fell 3.0% on the day and 10.1% on the week, WPM shed 3.5% and 13.7%, and EDV dropped 11.1% over five sessions. The move is sector-driven rather than Centerra-specific, which may actually soften the signal heading into the print.
Short positioning is low and largely benign. Short interest runs at just 1.6% of the free float — a level that has barely moved over the past month. Borrow costs, though, have roughly doubled from their one-month average, now at around 1.1% APR. Availability in the lending market remains very loose, however, which means no meaningful squeeze dynamics are in play. The ORTEX short score of 30 — modest by any standard — reinforces the picture: this is not a heavily shorted name where the print poses squeeze risk.
Where the story is more interesting is valuation and earnings quality. At a forward P/E of roughly 8.5x and an EV/EBITDA multiple near 4.1x, Centerra trades at a discount to most mid-tier gold producers. The EV/EBIT rank sits in the 98th percentile of the universe — meaning the stock looks cheap on operating earnings almost regardless of how you cut it. Consensus EPS estimates place Q1 earnings near CAD 0.91 per share on revenue of roughly $869 million. The company has a strong history of beating expectations, with an EPS surprise ranking in the 86th percentile, and the 90-day EPS momentum percentile is a healthy 77. Against that backdrop, the analyst mean price target of CAD 23.96 sits almost exactly at the current price, implying the Street sees neither meaningful upside nor downside from here — a neutral stance, not a bearish one.
The ownership picture adds modest context. Donald Smith & Co., a deep-value manager, holds 7.1% of shares and added 2.5 million shares last quarter — the most material institutional move in the recent data. FMR added 2.5 million shares through February. That combination of value-oriented anchors and low short interest suggests patient holders rather than momentum capital — a base less prone to sharp unwinds on a disappointing print.
The Q1 release will test whether Centerra's operational output and cost structure can sustain the margin profile that underpins that low-multiple valuation, particularly against a backdrop of gold price volatility and sector-wide de-risking.
See the live data behind this article on ORTEX.
Open CG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
